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OBJECTIVE — The potential beneﬁts of continuous glucose monitoring (CGM) in the man-
agement of adults and children with well-controlled type 1 diabetes have not been examined.
RESEARCH DESIGN AND METHODS — A total of 129 adults and children with
intensively treated type 1 diabetes (age range 8–69 years) and A1C 7.0% were randomly
assigned to either continuous or standard glucose monitoring for 26 weeks. The main study
outcomes were time with glucose level 70 mg/dl, A1C level, and severe hypoglycemic events.
RESULTS — At 26 weeks, biochemical hypoglycemia (70 mg/dl) was less frequent in the
CGM group than in the control group (median 54 vs. 91 min/day), but the difference was not
statisticallysigniﬁcant(P0.16).Mediantimewithaglucoselevel60mg/dlwas18versus35
min/day, respectively (P  0.05). Time out of range (70 or 180 mg/dl) was signiﬁcantly
lower in the CGM group than in the control group (377 vs. 491 min/day, P  0.003). There was
a signiﬁcant treatment group difference favoring the CGM group in mean A1C at 26 weeks
adjusted for baseline (P  0.001). One or more severe hypoglycemic events occurred in 10 and
11% of the two groups, respectively (P  1.0). Four outcome measures combining A1C and
hypoglycemia data favored the CGM group in comparison with the control group (P  0.001,
0.007, 0.005, and 0.003).
CONCLUSIONS — Most outcomes, including those combining A1C and hypoglycemia,
favored the CGM group. The weight of evidence suggests that CGM is beneﬁcial for individuals
with type 1 diabetes who have already achieved excellent control with A1C 7.0%.
Diabetes Care 32:1378–1383, 2009
O
ver the past 15 years, the use of
rapid and long-acting insulin ana-
logs, improvements in insulin
pumps, and more frequent home blood
glucose monitoring have had a positive
impact on the ability to achieve target
A1C levels in type 1 diabetes. However,
the rates of severe hypoglycemia remain
too high and the occurrence of such
events is often followed by a decline in
glycemic control due to fears of further
hypoglycemic episodes (1). Hypoglyce-
mia remains the major limiting factor
for achieving euglycemia in type 1 dia-
betes (2).
The introduction of new real-time
continuous glucose monitoring (CGM)
systems has generated great interest be-
cause these devices may have the poten-
tial to increase the proportion of patients
who are able to maintain target A1C val-
ueswhilesimultaneouslylimitingtherisk
of severe hypoglycemia. In a randomized
trial of 322 adults and children with type
1diabetesandbaselineA1Clevel7.0%,
our Juvenile Diabetes Research Founda-
tion (JDRF) Continuous Glucose Moni-
toring Study Group reported that CGM
substantially improved A1C levels with-
out increasing the frequency of hypogly-
cemiainadults25yearsofage,whereas
theloweringofA1Clevelsinchildrenand
adolescents was more limited (3). As with
virtually every other study of a new drug
or device in the treatment of type 1 dia-
betes, this study excluded individuals al-
ready reaching target A1C levels 7.0%
because lowering of A1C was the primary
outcome of interest. Consequently, our
study group also conducted a separate,
concurrent randomized trial to evaluate
the efﬁcacy and safety of CGM in adults
and children with type 1 diabetes who
already had successfully achieved A1C
levels 7.0% with intensive insulin
therapy.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the institutional review boards
of the 10 participating centers, which in-
cluded academic-, community-, and
managed care–based practices. Written
informed consent was obtained from
adult subjects and parents/guardians of
minor subjects. Minor subjects provided
written assent. Study procedures were
identical to those of a companion trial of
individuals with type 1 diabetes and A1C
7.0% (3,4). Key aspects of the study
protocol are described in the following.
Major eligibility criteria included age
8 years, type 1 diabetes for at least 1
year, use of either an insulin pump or at
least three daily insulin injections, and
baseline A1C level 7.0%. Subjects who
successfully completed a run-in phase of
“blinded” CGM use (a modiﬁed device in
which glucose values were recorded in
the receiver but were not visible to the
subject)wererandomlyassignedtoeither
the CGM group or the control group, us-
ing a permuted-blocks design stratiﬁed
by clinical center.
Subjects assigned to the CGM group
were provided with one of the following
devices: the DexCom SEVEN (DexCom,
San Diego, CA), the MiniMed Paradigm
REAL-Time Insulin Pump and Contin-
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tronic MiniMed, Northridge, CA), or the
FreeStyle Navigator (Abbott Diabetes
Care, Alameda, CA). Subjects were in-
structed to use the device on a daily basis
and to verify the accuracy of the glucose
measurement with a home blood glucose
meter (provided by the study) before
making management decisions (as per
the regulatory labeling of the devices).
Subjects in the control group were given
blood glucose meters and test strips and
asked to perform blood glucose monitor-
ing at least four times daily.
SubjectsinboththeCGMandcontrol
groups were provided with written in-
structions on how to use the CGM and
blood glucose meter data, respectively, to
make real-time insulin dose adjust-
mentsandonhowtousecomputersoft-
ware to retrospectively review the
glucose data to alter insulin dosing
(4,5). Although not required, all sub-
jects had a home computer.
The number of scheduled contacts
was identical for both treatment groups.
Visits were conducted at 1, 4, 8, 13, 19,
and26weeks(1week),withonesched-
uled phone contact between each visit, to
review glucose data and adjust diabetes
management. For 1 week, after the 13-
and 26-week visits, the control group
used one of the three real-time CGM de-
vices, modiﬁed such that the glucose val-
ues were recorded but not visible. An
additional sensor was used if fewer than
96 h of glucose values overall or 24 h
overnight were obtained. Central labora-
tory A1C was measured at baseline, 13
weeks, and 26 weeks at the University of
Minnesota using the Tosoh A1c 2.2 Plus
Glycohemoglobin Analyzer method (6).
Reportable adverse events included se-
vere hypoglycemia (deﬁned as an event
that required assistance from another in-
dividual to administer carbohydrate, glu-
cagon, or other resuscitative actions) (7),
hyperglycemia resulting in ketoacidosis,
unexpected study-related or device-
related events, and serious adverse events
regardless of causality.
Statistical methods
The primary outcome was the change in
the time per day with glucose values 70
mg/dl, comparing baseline sensor values
with those obtained after the 26-week
visit. A sample size of 120 subjects was
planned to have 90% power to detect a
difference in this outcome between treat-
ment groups, assuming a population dif-
ference of 29 min/day, SD of the 26-week
valuesof59min/day,correlationbetween
baseline and 26-week values of 0.66
(based on data from a prior study [8]), an
 level of 0.05, and no more than 15%
losses to follow-up.
Analyses followed the “intent-to-
treat” principle. Percentages of values less
than or greater than a given threshold
were converted to minutes per day by
multiplying by 1,440. As a result of the
skewness of the primary outcome data
(P  0.001 with the Shapiro-Wilk test), a
nonparametricapproachwasfollowedfor
the primary analysis using an ANCOVA
model based on ranks of the 26-week val-
ues using van der Waerden scores, ad-
justed for the baseline value, clinical
center, and type of continuous glucose
monitor. To assess for consistency, two
other analytic approaches were used in
ANCOVA models. In one, outlier values
were truncated at 288 min/day (20% of
the day), and in the other, a square root
transformation was performed. Other
outcomes based on the CGM data ob-
tained in both groups at baseline and 26
weekswereanalyzedsimilarly.Treatment
group differences in the rate of CGM-
based hypoglycemic events, deﬁned as
20 min with a blood glucose of 54
mg/dl (3.0 mmol/l) (9), were compared
with the nonparametric approach that
was used in the primary analysis.
Other preplanned secondary out-
comesincludedchangeinA1Cfrombase-
line to 26 weeks in an ANCOVA model
(adjusted for baseline A1C and clinical
center) and 26-week binary A1C out-
comes (decrease in A1C from baseline by
0.3%, increase in A1C from baseline by
0.3%,and26-weekvalue7.0%)eval-
uatedsimilarlyinlogisticregressionmod-
els. The 0.3% change was selected
because it exceeded the laboratory’s mea-
surementerrorandwasconsideredtobea
clinically meaningful change for an A1C
level 7.0%.
Analyses also were performed to as-
sess consistency of the treatment effect in
subgroups based on age (8–14, 15–24,
and25years).ChangeinCGMuseover
time was evaluated with a repeated-
measurements regression model. The as-
Figure 1—Combined A1C and hypoglycemia outcomes. Four outcomes are shown: A, combined
outcomeofA1Cimprovedby0.3%frombaselineto26weeksandnoseverehypoglycemicevents;
B, combined outcome of A1C improved by 0.3% from baseline to 26 weeks and CGM-measured
hypoglycemia (70 mg/dl) not increased from baseline to 26 weeks by 43 min/day (3% of the
day);C,combinedoutcomeofA1Cnotworseby0.3%andCGM-measuredhypoglycemia(70
mg/dl)decreasedfrombaselineto26weeksby43min/day(3%oftheday);D,combinedoutcome
of either B or C.
JDRF Continuous Glucose Monitoring Study Group
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evaluated with a Kruskal-Wallis test.
The proportions of subjects experi-
encing one or more severe hypoglycemic
eventsineachtreatmentgroupwerecom-
paredusingFisher’sexacttest.Incidences
of hypoglycemic events were compared,
and 95% CIs for the treatment group
difference were calculated using permu-
tation tests. Similar analyses were per-
formed for the subset of hypoglycemic
events associated with seizure or coma.
On a subject level, a reduction in
time 70 mg/dl was deﬁned as a de-
crease from baseline of 43 min/day
(3% of the day), and an increase like-
wise was deﬁned as an increase from
baseline of 43 min/day (representing
an50%changefromtheaveragebase-
line level). Four outcome measures
werecreatedbycombiningA1Candhy-
poglycemia data (as deﬁned in the leg-
end to Fig. 1) and compared between
treatment groups, using a logistic re-
gression model adjusting for baseline
A1C.
Analyses were performed using SAS
(version 9.1; SAS Institute, Cary, NC). All
P values are two-sided. Adjusting for im-
balancesbetweenbaselinefactorsandim-
puting for missing data using Rubin’s
method(10)didnotaltertheresults(data
not shown).
RESULTS— Between February and
December 2007, 129 children and adults
with type 1 diabetes were randomly as-
signedinthetrial:67wereassignedtothe
CGM group and 62 to the control group.
Baselinecharacteristicsoftheparticipants
are summarized in Table 1.
The visit completion rate was
99% in the CGM group and 98% in
the control group (supplementary Fig.
A1, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-0108/DC1), and the
phone contact completion rates were 98
and 95%, respectively. The 26-week visit
wascompletedbyallCGMgroupsubjects
and by all but two subjects in the control
group. No subjects in the CGM group
discontinued sensor use before the 26-
week visit, and no subjects in the control
group self-initiated CGM use before com-
pleting the 26-week visit. Self-reported
home glucose meter use was 7.3  2.4
measurements per day before study entry
and 7.1  3.5 measurements per day at
26 weeks in the CGM group compared
with 6.8  2.4 and 6.4  2.4 measure-
mentsperday,respectively,inthecontrol
group.
Glycemic control
Median time per day with a glucose level
70 mg/dl (as measured with CGM) de-
creasedfrom91minatbaselineto54min
at 26 weeks in the CGM group (P 
0.002) and from 96 to 91 min in the con-
trol group (P  0.43) (P  0.16 using
ranks, P  0.04 truncating outliers, and
P  0.06 using square root transforma-
tion). As seen in Table 2, there was stron-
ger statistical evidence of a treatment
groupdifferencefavoringtheCGMgroup
for other deﬁnitions of hypoglycemia
(time 60 mg/dl, time 50 mg/dl, and
area under the curve for 70 mg/dl) and
whentheCGMdatacollectedafterthe13-
and 26-week visits were pooled to pro-
vide a better indication of glycemic con-
trol over the 6 months than either time
point alone (supplementary Fig. A2,
available in an online appendix). A more
complete indication of the treatment
groupdifferencecanbeseeninthecumu-
lative distribution curves (supplementary
Figs. A3 and A4, available in the online
appendix). The CGM-based hypoglyce-
mia event rate (20 min with glucose
level 54 mg/dl [3.0 mmol/l], using the
CGM data collected during the week after
the 13- and 26-week visits) was 0.25 
0.40 events per 24 h in the CGM group
and 0.47  0.68 events per 24 h in the
control group (P  0.07).
There was a signiﬁcant difference be-
tween treatment groups in the mean A1C
level at 26 weeks adjusted for baseline
(P  0.001) (Table 3). Compared with
the control group, more subjects in the
CGM group had an improvement in A1C
of 0.3% (31 vs. 5%, P  0.001), fewer
had a worsening of A1C 0.3% (28 vs.
52%, P  0.002), and more had an A1C
level7.0%at26weeks(88vs.63%,P
0.001).
In three prespeciﬁed age-groups
(25, 15–24, and 8–14 years), results of
treatment group comparisons generally
were similar to those of the overall analy-
sis for the amount of time per day 70
mg/dl. Results also appeared similar in
subjects using multiple daily insulin in-
jections and in those using an insulin
pump, but the number of subjects using
injections was too small for a meaningful
comparison.
Table 1—Baseline characteristics of study subjects by treatment group
Treatment group
CGM Control
n 67 62
Female sex 36 (54) 32 (52)
Age (years) 29.3  16.3 32.0  17.7
25 34 (51) 33 (53)
15–24 15 (22) 18 (29)
8–14 18 (27) 11 (18)
Race: non-Hispanic white 63 (94) 58 (94)
Duration of diabetes by age-group
25 years old 25.6  16.6 28.6  12.7
15–24 years old 8.7  5.3 8.1  4.5
8–14 years old 4.9  2.6 4.4  3.2
Insulin modality
Pump 62 (93) 49 (79)
Multiple daily injections 5 (7) 13 (21)
Total daily dose of insulin by age-group (units/kg)
25 years old 0.5  0.1 0.5  0.1
15–24 years old 0.7  0.2 0.8  0.2
8–14 years old 0.8  0.1 0.8  0.3
A1C (%) 6.4  0.5 6.5  0.3
One or more severe hypoglycemia events* in last
6 months
7 (10) 7 (11)
Home glucose meter readings per day† 7.3  2.4 6.8  2.4
College graduate (subject or primary care giver) 58 (87) 55 (89)
Dataaren(%)ormeansSD.*Aseverehypoglycemiaeventwasdeﬁnedasaneventthatrequiredassistance
from another person to administer carbohydrate, glucagon, or other resuscitative actions. †Data were miss-
ing for six subjects in the CGM group and four in the control group.
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adverse events
Seven subjects (10%) in the CGM group
and seven (11%) in the control group ex-
perienced at least one severe hypoglyce-
mic event, with no signiﬁcant differences
comparing treatment groups (supple-
mentary Table A1, available in an online
appendix).Likewise,therewerenosignif-
icantdifferencescomparingtheincidence
rate of severe hypoglycemic events be-
tween treatment groups. There were no
serious adverse events attributable to the
study interventions.
Combined outcome measures
More subjects in the CGM group than in
the control group had a decrease in A1C
of 0.3% without experiencing a severe
hypoglycemic event (28 vs. 5%, P 
0.001). As seen in Fig. 1 (see also supple-
mentary Fig. A4, available in an online
appendix), more subjects in the CGM
groupthaninthecontrolgroupalsohada
decrease in A1C of 0.3% without an in-
crease of 43 min/day (3% of the day) in
CGM-measured glucose values 70
mg/dl (18 vs. 2%, P  0.007) and more
had a 43 min/day decrease in the time
per day with the glucose level 70 mg/dl
without an increase in A1C of 0.3% (29
vs. 15%, P  0.005).
Frequency of sensor use in the CGM
group
IntheCGMgroup,allsubjectswereusing
CGM at the end of the 26 weeks of the
study.TheamountofCGMusedecreased
slightly over the 26 weeks of the study
(P  0.001) but was still quite high after
26weeks.Duringtheﬁrst13weeksofthe
study, 78% of subjects averaged at least 6
days/week of CGM use compared with
67% during the ﬁnal 4 weeks. Only 13%
of subjects averaged 4 days a week dur-
ing the ﬁnal 4 weeks. Over the 26 weeks
of the study, median CGM use was 6.8
days/week in subjects 25 years old, 6.2
days/week in the 15–24 year olds, and
6.4 days/week in the 8–14 year olds (P 
0.07), averaging 6 days/week in 79, 53,
and 61%, respectively.
CONCLUSIONS — In this random-
ized trial, we evaluated the effect of CGM
on glycemic control in adults and chil-
dren with well-controlled type 1 diabetes
using conventional blood glucose moni-
toring, as evidenced by a baseline A1C
level 7.0%. For the primary outcome,
the median time per day 70 mg/dl as
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the CGM group than in the control group
after 6 months of intervention. Although
the prespeciﬁed primary analysis method
failed to reach statistical signiﬁcance,
other methods accounting for the skew-
ness of the data had smaller P values, and
signiﬁcant differences between groups
were seen with almost all other CGM-
measured biochemical hypoglycemic and
hyperglycemic outcomes as well as A1C
outcomes and outcomes combining A1C
and hypoglycemia.
In planning this study, the change in
A1C was not selected as the primary out-
come measure because we did not antici-
pate being able to lower A1C levels in the
CGMgroupinviewoftheirexquisitelevel
of control on entry in the study (4). In-
deed, we expected that there might even
be small and clinically insigniﬁcant in-
creasesinA1CvaluesintheCGMgroupif
we were able to reduce the frequency of
glucose levels 70 mg/dl. Instead, the
CGMgroupwasabletomaintainA1Clev-
els at baseline values with less biochemi-
cal hypoglycemia, whereas A1C levels
roseovertimeinthecontrolgroup.More-
over, all of the other A1C outcomes fa-
vored the CGM group over the control
group. The increases in A1C in the con-
trol group might have been expected be-
cause of regression to the mean from the
effective ﬂoor on the A1C level of 6.0%
for most patients and from the 6.9% A1C
cutoff point required for eligibility as well
as the difﬁculties in maintaining a near-
normal A1C level.
Lower A1C values in the CGM group
than in the control group were not asso-
ciated with an increased frequency of se-
vere hypoglycemic events, although the
trial was not formally powered to assess
for a treatment group difference in the
rate of severe hypoglycemia. It also is
noteworthy that the rates of severe hypo-
glycemia in both the CGM and control
groups in this study were less than half
those reported by the Diabetes Control
and Complications Trial, which may re-
ﬂect the beneﬁts of insulin analogs and
greater frequency of use of insulin pumps
in our population (7,11).
Thisstudyincludedauniquepopula-
tion of children, adolescents, and adults
with type 1 diabetes as noted by their en-
try A1C levels being 7.0% and their at-
tentiontointensivediabetesmanagement
principles with frequent blood glucose
monitoring at baseline, averaging about
seven times per day. Consistent with pre-
study management behaviors, adherence
to CGM use was high during this study in
subjects of all ages, although it was
slightly higher in adults than in children
and adolescents. This ﬁnding contrasts
with the results of our randomized trial
evaluating CGM in patients with type 1
diabetes and baseline A1C level 7.0%.
In that trial, CGM use was substantially
higherinadultsthaninchildren,and,asa
presumed consequence, the beneﬁt of
CGM in lowering A1C was greater in
adults than in children (3).
In summary, almost all analyses, al-
thoughnotthemethodpreselectedforthe
primary analysis, including the time per
day 60 mg/dl, time per day between 71
and 180 mg/dl, and analysis involving
A1C coupled with hypoglycemia, favored
the CGM group compared with the con-
trol group. Based on the weight of evi-
dence, CGM is beneﬁcial for adults and
childrenwithtype1diabeteswhoalready
have achieved excellent control with
home glucose monitoring.
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26 weeks (%) 6.4  0.5 6.8  0.5
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Decrease by 0.3% from baseline to
26 weeks
21 (31) 3 (5) 0.001
Increase by 0.3% from baseline to
26 weeks
19 (28) 31 (52) 0.002
Subjects who maintained A1C 7.0 at
26 weeks
59 (88) 38 (63) 0.001
Data are means  SD, difference (95% CI), or n (%). *26-week A1C data were not available for 2 subjects in
the control group. †ANCOVA model adjusted for baseline A1C and site. The negative value denotes lower
A1C in the CGM group compared with that in the control group.
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